Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.12)
# 1,262
Out of 5,048 analysts
38
Total ratings
45.16%
Success rate
3.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CADL Candel Therapeutics | Initiates: Overweight | $15 | $5.22 | +187.36% | 1 | Oct 28, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $23.91 | +46.38% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.48 | +141.94% | 3 | Sep 22, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $16 → $14 | $9.72 | +44.03% | 2 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $31.36 | +43.49% | 3 | Sep 9, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $30 | $12.62 | +137.72% | 4 | Jul 10, 2025 | |
| EXEL Exelixis | Upgrades: Overweight | $29 → $60 | $38.06 | +57.65% | 5 | Jun 24, 2025 | |
| DCTH Delcath Systems | Reiterates: Overweight | $25 | $9.52 | +162.61% | 3 | Jun 23, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $17.00 | +76.47% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $21.44 | +53.92% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $4.18 | +91.39% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $7.26 | +106.61% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $60 | $59.72 | +0.47% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.38 | +262.32% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $3.81 | +241.21% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $8.61 | +1,061.44% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.50 | +700.00% | 1 | May 14, 2024 |
Candel Therapeutics
Oct 28, 2025
Initiates: Overweight
Price Target: $15
Current: $5.22
Upside: +187.36%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $23.91
Upside: +46.38%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.48
Upside: +141.94%
Arvinas
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $14
Current: $9.72
Upside: +44.03%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $31.36
Upside: +43.49%
Nurix Therapeutics
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $12.62
Upside: +137.72%
Exelixis
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $38.06
Upside: +57.65%
Delcath Systems
Jun 23, 2025
Reiterates: Overweight
Price Target: $25
Current: $9.52
Upside: +162.61%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $17.00
Upside: +76.47%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $21.44
Upside: +53.92%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $4.18
Upside: +91.39%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $7.26
Upside: +106.61%
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $59.72
Upside: +0.47%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.38
Upside: +262.32%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $3.81
Upside: +241.21%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $8.61
Upside: +1,061.44%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.50
Upside: +700.00%